Drugs / HSVTK-tCD34 suicide gene modified donor T cells
HSVTK-tCD34 suicide gene modified donor T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01204502 | Jan 2011 → Jan 2013 | disease related to hematopoietic stem cell transplant | Great Ormond Street Hospital for Children NHS Foundation Trust | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSVTK-tCD34 suicide gene modified donor T cells | “These findings highlight the suitability of tCD34 as a GMP compliant selection marker and demonstrate the feasibility, safety and immunological potential of HSVTK-tCD34 suicide...” PMID 24204746 ↗ Oct 2013 |
| Modality | Cell therapy | “Engineered cells were administered in two escalating doses to three children receiving T-depleted, CD34 stem cell selected, mismatched allogeneic grafts.” PMID 24204746 ↗ Oct 2013 |